Oncology - FDA Grants REVLIMID® NDA Approval
Thu, 29 Dec 2005 08:00 PM EST
... Celgene Corporation (NASDAQ: CELG) announced that the FDA granted approval of REVLIMID (lenalidomide) which is indicated for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities... click link for more info. ...
Related Topics
- Vaccine Testing & Approval
- Tacrolimus ointment
- Mammography
- Carcinogens
- Cancer
- Tarceva
- Pimecrolimus Cream 1%
- Dietary Guidelines
- Radiotherapy
- Thalidomide
- Radiation
- Grants & Cooperative Agreements
- Grants
- Assistive Technology
- International Classification of Diseases
- Healing touch
- Food Labeling
- Drug Safety
- Yohimbe
- Food Labels

Not Signed In -


